A respected RNAi therapeutics company.

Alnylam presents interim data from ALN-VSP02 Stage I actually trial for liver malignancy at ASCO 2010 Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics company, today preliminary scientific data from its ongoing Phase I trial with ALN-VSP announced, a systemically shipped RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data are being offered at the ASCO achieving in a poster titled Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement, in the Developmental Therapeutics – Experimental Therapeutics poster session being held from 8:00 a http://prixcialis.com prixcialis.com .m.

Other Posts From Category "rehabilitation":

Related Posts

Aboutsmartdrugs.com